Docstoc

Newsletter-Radiopharmaceutical_Reports

Document Sample
Newsletter-Radiopharmaceutical_Reports Powered By Docstoc
					                            BIO -TECH SYSTEMS, INC.
                                      Market Research in the Health Care Field
     NEWS RELEASE                          4167 Pinecrest Circle West
     ─────────────────                     Las Vegas, Nevada 89121
      June 1, 2003                  ─────────────────────────
                                 (702) 456-7608         (702) 456-2189 FAX
                                    E-Mail: MBurns@biotechsystems.com
                                  Web Site: http://www.biotechsystems.com
───────────────────────────────────────────────────────────────────────────────
        FOR IMMEDIATE RELEASE                               Contact: Marvin Burns
                                                              Tel: (702) 456-7608
                                                              Fax: (702) 456-2189

          BIO-TECH SYSTEMS ANNOUNCES THE RELEASE OF TWO NEW REPORTS:
        Report 150: THE U.S MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS
        Report 160: THE U.S MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS
         ──────────────────────────────────────────────────────────────
            PRESENT AND EMERGING MARKET OPPORTUNITIES, NEW HIGH GROWTH
             PROSPECTS IN IMAGING AND THERAPY, TECHNOLOGICAL TRENDS AND
           COMPETITIVE CHALLENGES, INDUSTRY ANALYSIS AND SALES FORECASTS

        Bio-Tech Systems Inc. announces the publication of two comprehensive reports with detailed
        analysis of the markets for diagnostic and therapeutic radiopharmaceuticals. The diagnostic
        markets cover nuclear cardiology, neurology, functional nuclear medicine, targeted oncology
        and PET imaging. Therapeutic radiopharmaceuticals include both current and emerging
        applications for lymphoma colon cancer, lung cancer, bone cancer, endocrine cancer, brain
        cancer, liver cancer, pancreatic cancer and other cancers resistant to traditional therapies.
        Confidence in the prospects for therapeutic radiopharmaceuticals has overlapped into the
        diagnostic market, creating a stronger link between targeted imaging and complementary
        therapeutic products based on the same antibody or peptide. This has been a boon to nuclear
        medicine, since nuclear imaging is required in all cases to assess biodistribution and dosing of
        therapeutic radiopharmaceuticals, as well as evaluate patient response to therapy.

        Both reports have a strong focus on new products and technology and emerging market
        opportunities. Many of the new diagnostic agents have a therapeutic counterpart, allowing
        nuclear imaging, with feedback with respect to targeting. In addition, new diagnostic products
        in cardiology, neurology and functional nuclear medicine are also covered in detail. This
        includes novel approaches to assessing myocardial viability and infection imaging, as well as
        new products in neurology for diagnosing Parkinson’s and related neurological disorders
        The prospects for therapeutic radiopharmaceuticals are also on a major threshold with the
        approval of Zevalin for non-Hodgkins lymphoma. This will be followed by other radiotherapy
        products for both circulating and solid tumors, which should form a sound base for continued
        investment in this field. As these products enter the mainstream, there will be others in the
        pipeline for treating a variety of cancers. One motivator is the potential return on investment.
        The high pricing of these products is justified by their unique status and is indicative of future
        market opportunities, even in the presence of competition.


                                                          1                                      ---more---
Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects

U.S. sales of diagnostic radiopharmaceuticals reached $1.14 billion in 2002 and are expected to
rise to $2.94 billion by 2008. Radiopharmaceutical sales grew 15% in 2002 and should
increase to 20% by 2004-2005. This growth will be based on introduction of new products,
strong demand for cardiology procedures and increased sales of oncology products, particularly
FDG for PET imaging. Market growth should also benefit from higher prices for these new
products. In addition, more biopharmaceutical products will incorporate monoclonal antibody
and peptide-based targeted agents, expanding the range of nuclear procedures. This technical
influx will help all segments of nuclear medicine as nuclear imaging and therapy move closer
together. One effect is that clinicians will have more options as alternatives to higher risk and
more costly invasive procedures. This will stimulate more research and investment, adding
strength and stability to newer venture companies as well as those more established in the field.

Therapeutic Radiopharmaceuticals: Market Analysis and Future Prospects

U.S. sales of therapeutic radiopharmaceuticals were on the threshold in 2002 with the approval
of Zevalin for non-Hodgkins lymphoma. Total therapeutic product sales were $57 million in
2002, with rapid growth anticipated over the next 5-6 years. By 2008, therapeutic product sales
should reach $3.80 billion, exceeding diagnostic radiopharmaceutical sales by 30%. This will
be based on the introduction of new therapeutic radiopharmaceuticals for treating lymphoma,
colon cancer, lung cancer, bone cancer and other persistent cancers. These agents will be used
in conjunction with traditional therapies, enhancing their effectiveness, with better specificity
and reduced side effects. As interest in new therapeutic radiopharmaceuticals increases, it will
prompt investigators to consider different isotopes with more focused capabilities for treating
various tumors, reducing the bystander effect on neighboring healthy cells. Use of these new
agents will reduce treatment time and accelerate recovery for many patients. It will also offer
an attractive investment opportunity for many of the companies and venture groups supporting
these programs.

ABOUT THE AUTHOR

Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in
the healthcare field. Burns specializes in market evaluation, where technological and scientific
insight is important. The company has prepared numerous market research reports on
diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional
cardiology and medical imaging, which have been widely distributed. Burns has also served as
a consultant to many international firms and venture groups in these fields. He has also been
Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical
and biotechnology industry reporting on new developments in cancer diagnosis and treatment.
Burns is a graduate of MIT and Harvard Business School’s advanced management program.
He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to
forming Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and
medical imaging fields in general management, marketing and product development. He was
also a hospital administrator in charge of professional and technical services including medical
imaging, clinical laboratories, therapy services, and materials management.



                                                2                                       ---more---
         DIAGNOSTIC RADIOPHARMACEUTICALS: REPORT CONTENTS

SECTION I: Market Status, Trends and Forecasts
Analysis of recent sales, competitive challenges, new products in the pipeline and forces
affecting future growth. Also provides sales forecasts to 2008. Products include:
     Nuclear cardiology (heart perfusion agents, pharmacologic stressors, blood pool agents,
      myocardial viability agents, thrombus imaging and metabolic FDG imaging.
     Functional nuclear medicine and cancer imaging (antibody and peptide-based products,
      NeoTect, ProstaScint, AcuTect, Octreoscan, CEA-Scan and FDG imaging.
     Neurology Imaging (New products for Parkinson’s and related syndromes, FDG imaging.
SECTION II: Radiopharmaceutical Products and Technology
     Technical principles and functional characteristics of radiopharmaceutical agents.
     Radioisotope selection and optimization; production methods and trade-offs.
     Analysis of emerging technologies and their probable impact on future markets.
SECTION III: Clinical Applications
     Discussion of clinical applications for radiopharmaceutical products and technologies.
     Options in radiopharmaceutical selection and opportunities in PET imaging.
     Analysis of product characteristics, performance benefits and trade-offs.
SECTION IV: Current Developments and Emerging Technologies
     Description of products in development within each major market segment including
      nuclear cardiology, neurology, targeted cancer imaging and infection imaging.
     Interaction of diagnostic and therapeutic agents, selection of isotopes and new targeting
      methodologies.
     Description of new technologies for diagnostic agents, such as receptor-specific proteins,
      antibodies and peptides, new cellular viability agents for cardiology, pretargeting in
      cancer imaging for increased dose delivery, and agents for imaging cellular necrosis.
SECTION V: Industry Analysis
     Analysis of current suppliers with individual product sales and market shares in 2002
     Market distribution, pricing strategies and new products in the pipeline.
     Discussion of marketing goals, product plans, corporate partnerships and new ventures.
SECTION VI: End-User Analysis
     Analysis of end-user groups and comparative requirements for medical imaging.
     Procedure mix and product utilization in hospitals and clinics.
SECTION VII: Company Profiles
     Background information on companies in the field and review of recent performance.
     Discussion of each company's market activities and management strategies



                                                 3                                         ---more---
  PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS

HISTORICAL AND FORECAST GROWTH OF         TARGETED CANCER IMAGING BY PRODUCT
RADIOPHARMACEUTICAL SALES FROM            GROUP FROM 1997-2008
1997-2008
                                          2002 SALES AND MARKET SHARES OF
COMPARATIVE SALES GROWTH OF               RADIOPHARMACY COMPANIES AND
DIAGNOSTIC ANDTHERAPEUTIC RADIO-          INDEPENDENT NUCLEAR PHARMACIES
PHARMACEUTICALS AND BRACHY-
THERAPY PRODUCTS FROM 1997-2008           ANALYSIS OF RADIOPHARMACY REVENUE,
                                          COSTS AND GROSS PROFIT IN 2002
HISTORIC AND FORECAST SALES GROWTH
OF DIAGNOSTICRADIOPHARMACEUTICALS         DISTRIBUTION OF RADIOPHARMA-
BY PRODUCT GROUP FROM 1997-2008           CEUTICAL SALES IN THE U.S. IN 2002,
                                          MANUFACTURER'S SALES DOLLAR
2002 DIAGNOSTIC RADIOPHARMA-              VOLUME BY PRODUCT CATEGORY
CEUTICAL SALES SUMMARY BY
PROCEDURE AND PRODUCT TYPE                2002 SALES OF THALLIUM FOR HEART
                                          PERFUSION STUDIES, RADIOPHARMA-
2008 DIAGNOSTIC RADIOPHARMA-              CEUTICAL SUPPLIER AND MARKET SHARE
CEUTICAL SALES SUMMARY BY
PROCEDURE AND PRODUCT TYPE                2002 SALES OF CARDIOLITE FOR HEART
                                          PERFUSION STUDIES, RADIOPHARMA-
HISTORIC AND FORECAST SALES GROWTH        CEUTICAL SUPPLIER AND MARKET SHARE
OF NUCLEAR CARDIOLOGY AND
VASCULAR IMAGING BY PRODUCT               2002 SALES OF MYOVIEW FOR HEART
CATEGORY FROM 1997-2008                   PERFUSION STUDIES, RADIOPHARMA-
                                          CEUTICAL SUPPLIER AND MARKET SHARE
HISTORIC AND FORECAST SALES OF
CARDIAC PERFUSION AND BLOOD POOL          2002 SALES OF CARDIOGEN, RUBIDIUM-81
AGENTS BY PRODUCT FROM 1997-2008          GENERATOR, FOR HEART PERFUSION
                                          STUDIES, RADIOPHARMACEUTICAL
HISTORIC AND FORECAST SALES OF            SUPPLIER AND MARKET SHARE
PHARMACOLOGIC STRESSORS FOR
CARDIAC IMAGING BY PRODUCT                2002 SALES OF PERSANTINE FOR
CATEGORY FROM 1997-2008                   PHARMACOLOGIC STRESS, RADIOPHARMA-
                                          CEUTICAL SUPPLIER AND MARKET SHARE
SALES OF CARDIOLOGY AGENTS FOR
MYOCARDIAL VIABILITY, THROMBUS AND        2002 SALES OF ADENOSINE FOR
VASCULAR IMAGING BY PRODUCT GROUP         PHARMACOLOGIC STRESS, SUPPLIER AND
FROM 1997-2008                            MARKET SHARE

SALES OF GENERAL NUCLEAR MEDICINE         2002 SALES OF GENERIC DIPYRIDAMOLE
PRODUCTS FOR FUNCTIONAL STUDIES AND       FOR PHARMACOLOGIC STRESS,
TARGETED IMAGING FROM 1997-2008           RADIOPHARMACEUTICAL SUPPLIER AND
                                          MARKET SHARE
HISTORIC AND FORECAST SALES OF
ISOTOPE PRODUCTS FOR FUNCTIONAL           2002 SALES OF PYP-PYROPHOSPHATE KITS
IMAGING, BY PRODUCT FROM 1997-2008        FOR HEART IMAGING, RADIOPHARMA-
                                          CEUTICAL SUPPLIER AND MARKET SHARE
HISTORIC AND FORECAST SALES OF
TECHNETIUM AND TECHNETIUM KITS FOR
GENERAL PURPOSE IMAGING BY PRODUCT
CATEGORY FROM 1997-2008

HISTORIC AND FORECAST SALES OF FDG,
ANTIBODIES AND PEPTIDES FOR

                                      4                                    ---more---
   PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS

2002 SALES OF TECHNETIUM GENERATORS,         2002 SALES OF XENON FOR LUNG
RADIOPHARMACEUTICAL SUPPLIER AND             VENTILATION STUDIES,RADIOPHARMA-
MARKET SHARE                                 CEUTICAL SUPPLIER AND MARKET SHARE

2002 SALES OF MDP AND HDP KITS FOR           2002 SALES OF INDIUM OXINE FOR
BONE IMAGING, RADIOPHARMACEUTICAL            IMAGING INFLAMMATORY PROCESSES,
SUPPLIER AND MARKET SHARE                    RADIOPHARMACEUTICAL SUPPLIER AND
                                             MARKET SHARE
2002 SALES OF TECHNETIUM DTPA KITS
FOR AEROSOL LUNG VENTILATION, BRAIN          2002 SALES OF PROSTASCINT FOR IMAGING
AND KIDNEY SCANS, RADIIOPHARMA-              PROSTATE CANCER, RADIOPHARMA-
CEUTICAL SUPPLIER AND MARKET SHARE           CEUTICAL SUPPLIER AND MARKET SHARE

2002 SALES OF TECHNETIUM SULFUR              2002 SALES OF CEA SCAN FOR IMAGING
COLLOID KITS FOR LIVER SCANS,                COLORECTAL CANCER, RADIOPHARMA-
RADIOPHARMACEUTICAL SUPPLIER AND             ACEUTICAL SUPPLIER AND MARKET SHARE
MARKET SHARE
                                             2002 SALES OF OCTREOSCAN FOR IMAGING
2002 SALES OF MACRO-AGGREGATED               NEUROENDOCRINE TUMORS,
ALBUMIN FOR LUNG PERFUSION SCANS,            RADIOPHARMACEUTICAL SUPPLIER AND
RADIOPHARMACEUTICAL SUPPLIER AND             MARKET SHARE
MARKET SHARE
                                             2002 SALES OF NEOTECT FOR LUNG
2002 SALES OF TECHNETIUM BILIARY             CANCER, RADIOPHARMACEUTICAL
AGENTS FOR GALL BLADDER STUDIES,             SUPPLIER AND MARKET SHARE
RADIOPHARMACEUTICAL SUPPLIER AND
MARKET SHARE                                 2002 SALES OF INDIUM CHLORIDE FOR
                                             COMPOUNDING WITH CANCER IMAGING
2002 SALES OF TECHNESCAN MAG-3 FOR           AGENTS, RADIOPHARMACEUTICAL
KIDNEY FUNCTION STUDIES, RADIO-              SUPPLIER AND MARKET SHARE
MACEUTICAL SUPPLIER AND MARKET
SHARE                                        2002 SALES OF FDG FOR METABOLIC
                                             IMAGING IN ONCOLOGY, NEUROLOGY AND
2002 SALES OF IODINE 131 FOR THYROID         CARDIOLOGY, RADIOPHARMACEUTICAL
IMAGING AND KIDNEY SCANS, RADIO-             SUPPLIER AND MARKET SHARE
PHARMACEUTICAL SUPPLIER AND
MARKET SHARE                                 COMPARATIVE ALLOCATION OF
                                             DIAGNOSTIC FACILITIESBY HOSPITAL BED
2002 SALES OF I-123 FOR THYROID SCANS,       SIZE
RADIOPHARMACEUTICAL SUPPLIER-,
SALES VOLUME AND MARKET SHARE                COMPARATIVE UTILIZATION PARAMETERS
                                             FOR DIFFERENT IMAGING MODALITIES IN
2002 SALES OF CERETEC FOR BRAIN              2002
PERFUSION STUDIES AND WHITE BLOOD
CELL LABELING, RADIOPHARMACEUTICAL           RELATIVE PROCEDURE VOLUME AMONG
SUPPLIER AND MARKET SHARE                    DIFFERENT IMAGING MODALITIES, RALA-
                                             TIONSHIP BY HOSPITAL BED SIZE IN 2002
2002 SALES OF NEUROLITE FOR BRAIN
PERFUSION STUDIES, RADIOPHARMA-              2002 DISTRIBUTION OF NUCLEAR
CEUTICAL SUPPLIER AND MARKET SHARE           MEDICINE PROCEDURES IN HOSPITALS
                                             AND IMAGING CLINICS
2002 SALES OF GALLIUM FOR TUMORS,
ABSCESSES AND INFLAMMATION,
PRODUCT SUPPLIER AND MARKET SHARE


                                         5                                    ---more---
       THERAPEUTIC RADIOPHARMACEUTICALS: REPORT CONTENTS

SECTION I: Market Status, Trends and Forecasts
Analysis of current and emerging markets for therapeutic radiopharmaceuticals. Discussion
of market prospects by product group and disease category. Review of new products in the
pipeline, projections for FDA approval and sales forecasts in all categories to 2008. This
includes:
     Analysis of market prospects for new targeted radiotherapy agents that have been
      approved or in development. Applications include lymphoma, colon cancer, lung
      cancer, bone cancer, myeloma, endocrine cancer and other cancers resistant to
      traditional therapies.
     Projections for new products using novel targeting technologies for treating bone
      cancer, brain cancer, pancreatic cancer and other cancers that may benefit from these
      modalities.
     Prospects for new radiotherapies employing isotopes optimized for the application with
      reduced damage to bystander cells, including lutetium-177, holmium-166, rhenium-188,
      bismuth 213 and astatine-211.
     Discussion of product pricing, competitive factors and return on investment.
SECTION II: Analysis of Procedure Volume
     Discussion of incidence of disease and relationship to potential radiotherapy procedures.
      Forecast procedure volume by disease category from 2002-2008 with discussion of
      rationale for these projections.
     Comparative procedure volume for brachytherapy by product application including
      prostate seed implants, endovascular brachytherapy, post-surgical brachytherapy and
      irradiated microsphere infusion.
SECTION III: Radiopharmaceutical Products and Technology
     Technical principles and functional characteristics of therapeutic radiopharmaceuticals.
     New options in selecting therapeutic isotopes for specific applications.
SECTION IV: Current Developments and Emerging Technology
     Discussion of new therapeutic radiopharmaceuticals in development, with analysis of
      technological prospects and potential applications. .
     Analysis of product characteristics, performance benefits and trade-offs relative to
      various therapeutic applications.
SECTION V: END-USER ANALYSIS
     Analysis of end-user groups and comparative requirements for radiotherapy products.
     Procedure mix and product utilization in hospitals and clinics.
SECTION VI: Company Profiles
     Background information on companies in the field and review of recent performance.
     Discussion of each company's market activities and management strategies.


                                                 6                                       ---more---
  PARTIAL LIST OF EXHIBITS: THERAPEUTIC RADIOPHARMACEUTICALS

HISTORIC AND FORECAST SALES GROWTH           PROCEDURE GROWTH OF THERAPEUTIC
OF THERAPEUTIC RADIOPHARMA-                  RADIOPHARMACEUTICALS FOR COLON
CEUTICALS FROM 1997-2008 (Graph)             CANCER, LUNG CANCER, PROSTATE, LIVER
                                             AND SOLID TUMORS BY PODUCT TYPE
COMPARATIVE SALES GROWTH OF                  FROM 2003-2008
DIAGNOSTIC AND THERAPEUTIC
RADIOPHARMACEUTICALS AND                     FORECAST SALES OF THERAPEUTIC
BRACHYTHERAPY FROM 1997-2008                 RADIOPHARMACEUTICALS FOR MYELOMA,
                                             MELANOMA, BONE CANCER, AND
2002 THERAPEUTIC RADIOPHARMA-                ENDOCRINE CANCER BY PRODUCT TYPE
CEUTICAL SALES SUMMARY BY                    FROM 2003-2008
PROCEDURE AND PRODUCT TYPE
                                             FORECAST SALES OF THERAPEUTIC
2008 THERAPEUTIC RADIOPHARMA-                RADIOPHARMACEUTICALSFOR MYELOMA,
CEUTICALS SALES SUMMARYBY                    MELANOMA, BONE CANCER, AND
PROCEDURE AND PRODUCT TYPE                   ENDOCRINE CANCER BY PRODUCT TYPE
                                             FROM 2003-2008 (Graph)
FORECAST SALES OF TARGETED
THERAPEUTIC RADIOPHARMACEUTICALS             PROCEDURE GROWTH OF THERAPEUTIC
BY DISEASE TYPE FROM 2002-2008               RADIOPHARMACEUTICALS FOR MYELOMA,
                                             BONE CANCER AND ENDOCRINE CANCER
FORECAST SALES OF TARGETED                   BY PRODUCT TYPE FROM 2003-2008
THERAPEUTIC RADIOPHARMACEUTICALS
BY DISEASE TYPE FROM 2003-2008 (Graph)       HISTORIC AND FORECAST SALES GROWTH
                                             OF BONE PAIN PALLIATION
FORECAST GROWTH OF TARGETED                  RADIOTHERAPY AGENTS BY PRODUCT
RADIOTHERAPY PROCEDURES BY TYPE OF           TYPE FROM 1997-2008
DISEASE FROM 2002-2008
                                             HISTORIC AND FORECAST SALES GROWTH
FORECAST SALES GROWTH OF LYMPHOMA            OF BONE PAIN PALLLIATION
IMMUNO-THERAPY AGENTS BY                     RADIOTHERAPY AGENTS FROM 1997-2008
MANUFACTURER AND PRODUCT TYPE                (Graph)
FROM 2002-2008
                                             GROWTH OF TARGETED RADIOTHERAPY
FORECAST SALES GROWTH OF LYMPHOMA            PROCEDURE VOLUME BY PRODUCT
AGENTS BY PRODUCT TYPE FROM 1997-            APPLICATION FROM 2002-2008
2008 (Graph)
                                             GROWTH OF BRACHYTHERAPY
FORECAST GROWTH OF LYMPHOMA                  PROCEDURE VOLUME BY PRODUCT
RADIO-THERAPY PROCEDURES BY                  APPLICATION FROM 2002-2008
MANUFACTURER AND PRODUCT TYPE
FROM 2002-2008                               COMPARATIVE ALLOCATION OF
                                             DIAGNOSTIC FACILITIES BY HOSPITAL BED
FORECAST SALES OF THERAPEUTIC                SIZE IN 2002
RADIOPHARMACEUTICALSFOR COLON
CANCER, LUNG CANCER, PROSTATE, LIVER         COMPARATIVE UTILIZATION PARAMETERS
AND SOLID TUMORS BY PRODUCT TYPE             FOR DIFFERENT IMAGING MODALITIES IN
FROM 2003-2008                               2002

SALES GROWTH OF THERAPEUTIC                  RELATIVE PROCEDURE VOLUME FOR
RADIOPHARMACEUTICALS FOR COLON               DIFFERENT IMAGING MODALITIES,
CANCER, LUNG CANCER, PROSTATE, LIVER         PERCENTAGE RELATIONSHIP BY HOSPITAL
AND SOLID TUMORS BY PRODUCT TYPE             BED SIZE IN 2002
FROM 2003-2008 (Graph)


                                         7                                  ---more---
                         COMPANY PROFILES INCLUDE


AMERSHAM HEALTH                          IDEC PHARMACEUTICALS

ANTISOMA, LTD. (UK)                      IMAGYN MEDICAL TECHNOLOGIES

BERLEX LABORATORIES                      IMMUNOMEDICS, INC.

CIS BiO-INTERNATIONAL (BERLEX)           LYNNTECH, INC.

DIATIDE RESEARCH LABS (BERLEX)           MALLINCKRODT INC. (TYCO)

BEST MEDICAL INTERNATIONAL               MDS NORDION

BIOSTREAM, INC.                          MENTOR CORPORATION

BOSTON LIFE SCIENCEOS, INC.              NEORX CORPORATION

BRACCO DIAGNOSTICS                       NORTH AMERICAN SCIENTIFIC,

C.R. BARD                                NOVOSTE CORPORATION

COPHAROS, INC                            PALATIN TECHNOLOGIES INC

CORDIS DIVISION OF J&J                   PEREGRINE PHARMACEUTICALS

CORIXA CORPORATION                       PETNet PHARMACEUTICALS, INC.

CYTOGEN CORPORATION                      PROXIMA THERAPEUTICS INC.

DOW CHEMICAL CO.                         SIRTEX MEDICAL LTD. (Australian)

DRAXIMAGE, INC.                          SYNCOR INT’L (CARDINAL HEALTH)

DUPONT IMAGING (BRISTOL MYERS)           THERAGENICS CORPORATION

FUJISAWA USA INC.                        VITA MEDICAL (Australian)

GUIDANT CORPORATION




                                     8
                                      ORDER FORM

Report No. 150 — THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS
Report No. 160 — THE U.S. MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS
Report No. 170 — THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS
Each report is priced at $4,500 including postage. Extra copies are priced at $750 each.
Please make checks payable to: BIO-TECH SYSTEMS, INC.
For wire transfer, make deposit to:
       BANK OF AMERICA, NEVADA
       Post Office Box 98600
       Las Vegas, Nevada 89193-8600
       Routing/ABA #122 400 724
For credit to: BIO-TECH SYSTEMS, INC.,
Account No. 270 113 178

Mailing Information

Name:______________________________Title:_____________________________________
Company:____________________________________________________________________
Address______________________________________________________________________
City:_______________________State________Zip Code__________Country_____________
Telephone_______________________________FAX_________________________________
E-Mail_______________________________________________
P.O. #:______________________________Signature_________________________________

Credit Cards: VISA, MC, AMEX, DISCOVER (Check One)
Credit Card No._______________________________________________________________
Expiration: Month_______Year_____Name on Card :_________________________________
Signature____________________________________________________________________
Address for Credit Card Statements________________________________________________
____________________________________________________________________________

Return to:
                                BIO-TECH SYSTEMS, INC.
                                  4167 W. Pinecrest Circle
                                 Las Vegas, Nevada 89121
                  Telephone: (702) 456-7608          FAX (702) 456-2189
                           E-Mail: MBurns@biotechsystems.com




                                                9

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:0
posted:4/28/2013
language:Unknown
pages:9
tao peng tao peng fuzhou http://
About 1234567